

Christopher I Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7919714/publications.pdf>

Version: 2024-02-01

145
papers

9,532
citations

46918

47
h-index

40881

93
g-index

152
all docs

152
docs citations

152
times ranked

11309
citing authors

#	ARTICLE	IF	CITATIONS
1	US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. Journal of the National Cancer Institute, 2014, 106, .	3.0	969
2	Differences in Breast Cancer Stage, Treatment, and Survival by Race and Ethnicity. Archives of Internal Medicine, 2003, 163, 49.	4.3	576
3	Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Research, 2007, 9, R6.	2.2	576
4	Trends in Incidence Rates of Invasive Lobular and Ductal Breast Carcinoma. JAMA - Journal of the American Medical Association, 2003, 289, 1421.	3.8	434
5	Discovery of common and rare genetic risk variants for colorectal cancer. Nature Genetics, 2019, 51, 76-87.	9.4	377
6	Relationship Between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast Cancer. JAMA - Journal of the American Medical Association, 2003, 289, 3254.	3.8	346
7	Disparities in breast cancer characteristics and outcomes by race/ethnicity. Breast Cancer Research and Treatment, 2011, 127, 729-738.	1.1	245
8	Incidence of Invasive Breast Cancer by Hormone Receptor Status From 1992 to 1998. Journal of Clinical Oncology, 2003, 21, 28-34.	0.8	220
9	Array Comparative Genomic Hybridization Analysis of Genomic Alterations in Breast Cancer Subtypes. Cancer Research, 2004, 64, 8541-8549.	0.4	197
10	Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nature Communications, 2020, 11, 597.	5.8	193
11	Reproductive History and Oral Contraceptive Use in Relation to Risk of Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2011, 103, 470-477.	3.0	190
12	Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer, 2000, 88, 2570-2577.	2.0	179
13	Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer, 2006, 106, 2104-2112.	2.0	167
14	Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer, 2000, 88, 2561-2569.	2.0	138
15	Association of Digital Breast Tomosynthesis vs Digital Mammography With Cancer Detection and Recall Rates by Age and Breast Density. JAMA Oncology, 2019, 5, 635.	3.4	136
16	Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer, 2003, 98, 1504-1513.	2.0	131
17	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. Journal of the National Cancer Institute, 2019, 111, 146-157.	3.0	129
18	Age-Specific Incidence Rates of In situ Breast Carcinomas by Histologic Type, 1980 to 2001. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1008-1011.	1.1	126

#	ARTICLE	IF	CITATIONS
19	Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. <i>American Journal of Human Genetics</i> , 2020, 107, 432-444.	2.6	124
20	Racial Disparities in Breast Cancer Diagnosis and Treatment by Hormone Receptor and HER2 Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1666-1672.	1.1	122
21	Alcohol Consumption and Risk of Postmenopausal Breast Cancer by Subtype: The Women's Health Initiative Observational Study. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1422-1431.	3.0	121
22	Relationship Between Potentially Modifiable Lifestyle Factors and Risk of Second Primary Contralateral Breast Cancer Among Women Diagnosed With Estrogen Receptor–Positive Invasive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5312-5318.	0.8	117
23	Reproductive and hormonal risk factors for postmenopausal luminal, HER2–overexpressing, and triple–negative breast cancer. <i>Cancer</i> , 2008, 113, 1521-1526.	2.0	114
24	Use of Antihypertensive Medications and Breast Cancer Risk Among Women Aged 55 to 74 Years. <i>JAMA Internal Medicine</i> , 2013, 173, 1629.	2.6	110
25	Cumulative Burden of Colorectal Cancer–Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. <i>Gastroenterology</i> , 2020, 158, 1274-1286.e12.	0.6	110
26	Body Size and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer in Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2078-2086.	1.1	101
27	Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20–44 years of age. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 579-587.	1.1	101
28	Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002, 11, 601-7.	1.1	96
29	Changing Incidence of Lobular Carcinoma in situ of the Breast. <i>Breast Cancer Research and Treatment</i> , 2002, 75, 259-268.	1.1	94
30	Changes in Breast Cancer Incidence Rates in the United States by Histologic Subtype and Race/Ethnicity, 1995 to 2004. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 2773-2780.	1.1	93
31	Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses. <i>Gastroenterology</i> , 2020, 158, 1300-1312.e20.	0.6	90
32	Risk of Mortality by Histologic Type of Breast Cancer Among Women Aged 50 to 79 Years. <i>Archives of Internal Medicine</i> , 2003, 163, 2149.	4.3	87
33	Timing of Menarche and First Full-Term Birth in Relation to Breast Cancer Risk. <i>American Journal of Epidemiology</i> , 2007, 167, 230-239.	1.6	83
34	Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. <i>BMC Medicine</i> , 2020, 18, 396.	2.3	76
35	Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age. <i>Cancer Research</i> , 2014, 74, 4078-4089.	0.4	74
36	Relationship between Menopausal Hormone Therapy and Risk of Ductal, Lobular, and Ductal-Lobular Breast Carcinomas. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 43-50.	1.1	70

#	ARTICLE	IF	CITATIONS
37	Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 607-617.	1.1	69
38	Senescence-associated tissue microenvironment promotes colon cancer formation through the secretory factor GDF15. <i>Aging Cell</i> , 2019, 18, e13013.	3.0	69
39	Effect of Depo-Medroxyprogesterone Acetate on Breast Cancer Risk among Women 20 to 44 Years of Age. <i>Cancer Research</i> , 2012, 72, 2028-2035.	0.4	67
40	Breast cancer characteristics and outcomes among Hispanic Black and Hispanic White women. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 1297-1304.	1.1	64
41	Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 545-554.	1.1	64
42	Early-Phase Studies of Biomarkers: What Target Sensitivity and Specificity Values Might Confer Clinical Utility?. <i>Clinical Chemistry</i> , 2016, 62, 737-742.	1.5	61
43	Evaluation of Known Oncoantibodies, HER2, p53, and Cyclin B1, in Prediagnostic Breast Cancer Sera. <i>Cancer Prevention Research</i> , 2012, 5, 1036-1043.	0.7	57
44	Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors. <i>Gynecologic Oncology</i> , 2016, 140, 138-144.	0.6	56
45	Reproductive and anthropometric factors in relation to the risk of lobular and ductal breast carcinoma among women 65-79 years of age. <i>International Journal of Cancer</i> , 2003, 107, 647-651.	2.3	51
46	Interactions between Body Mass Index and Hormone Therapy and Postmenopausal Breast Cancer Risk (United States). <i>Cancer Causes and Control</i> , 2006, 17, 695-703.	0.8	49
47	Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 353-361.	157.7	49
48	Active smoking and the risk of estrogen receptor-positive and triple-negative breast cancer among women ages 20 to 44 years. <i>Cancer</i> , 2014, 120, 1026-1034.	2.0	48
49	The ColoCare Study: A Paradigm of Transdisciplinary Science in Colorectal Cancer Outcomes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 591-601.	1.1	48
50	Dysfunctional epigenetic aging of the normal colon and colorectal cancer risk. <i>Clinical Epigenetics</i> , 2020, 12, 5.	1.8	47
51	Relationship between Age Maximum Height Is Attained, Age at Menarche, and Age at First Full-Term Birth and Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 2144-2149.	1.1	45
52	Antidepressant use and breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2006, 95, 131-140.	1.1	44
53	Genetic variant predictors of gene expression provide new insight into risk of colorectal cancer. <i>Human Genetics</i> , 2019, 138, 307-326.	1.8	44
54	Genetic architectures of proximal and distal colorectal cancer are partly distinct. <i>Gut</i> , 2021, 70, 1325-1334.	6.1	44

#	ARTICLE	IF	CITATIONS
55	Risk Factors for Ductal, Lobular, and Mixed Ductal-Lobular Breast Cancer in a Screening Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1643-1654.	1.1	43
56	Risk of Mortality by Histologic Type of Breast Cancer in the United States. <i>Hormones and Cancer</i> , 2010, 1, 156-165.	4.9	42
57	Cross-Species Antibody Microarray Interrogation Identifies a 3-Protein Panel of Plasma Biomarkers for Early Diagnosis of Pancreas Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1764-1771.	3.2	42
58	Relationship between Radiation Exposure and Risk of Second Primary Cancers among Atomic Bomb Survivors. <i>Cancer Research</i> , 2010, 70, 7187-7198.	0.4	41
59	Improving the Quality of Biomarker Discovery Research: The Right Samples and Enough of Them. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 944-950.	1.1	41
60	Genetic Polymorphisms in the Catechol Estrogen Metabolism Pathway and Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1461-1467.	1.1	40
61	The Relationship Between Various Measures of Cigarette Smoking and Risk of Breast Cancer Among Older Women 65-79 years of Age (United States). <i>Cancer Causes and Control</i> , 2005, 16, 975-985.	0.8	39
62	Migraine in Postmenopausal Women and the Risk of Invasive Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 3116-3122.	1.1	38
63	Adjuvant Hormonal Therapy for Breast Cancer and Risk of Hormone Receptor-Specific Subtypes of Contralateral Breast Cancer. <i>Cancer Research</i> , 2009, 69, 6865-6870.	0.4	37
64	Detection of Elevated Plasma Levels of Epidermal Growth Factor Receptor Before Breast Cancer Diagnosis among Hormone Therapy Users. <i>Cancer Research</i> , 2010, 70, 8598-8606.	0.4	37
65	Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis. <i>Supportive Care in Cancer</i> , 2017, 25, 75-83.	1.0	36
66	Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. <i>Gastroenterology</i> , 2021, 160, 1164-1178.e6.	0.6	36
67	Racial and ethnic disparities in breast cancer stage, treatment, and survival in the United States. <i>Ethnicity and Disease</i> , 2005, 15, S5-9.	1.0	35
68	Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 185-193.	1.1	34
69	Reproductive Factors and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer Among Multiethnic Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1297-1304.	1.1	33
70	Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis. <i>Cancer Research</i> , 2017, 77, 6033-6041.	0.4	33
71	Birthweight and risk of overall and cause-specific childhood mortality. <i>Paediatric and Perinatal Epidemiology</i> , 2003, 17, 164-170.	0.8	29
72	Relationship between Migraine History and Breast Cancer Risk among Premenopausal and Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2030-2034.	1.1	29

#	ARTICLE	IF	CITATIONS
73	Circulating bilirubin levels and risk of colorectal cancer: serological and Mendelian randomization analyses. <i>BMC Medicine</i> , 2020, 18, 229.	2.3	28
74	Genetically predicted circulating concentrations of micronutrients and risk of colorectal cancer among individuals of European descent: a Mendelian randomization study. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1490-1502.	2.2	27
75	Implications of Epigenetic Drift in Colorectal Neoplasia. <i>Cancer Research</i> , 2019, 79, 495-504.	0.4	26
76	Mendelian Randomization of Circulating Polyunsaturated Fatty Acids and Colorectal Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 860-870.	1.1	26
77	Bisphosphonate Use After Estrogen Receptor-Positive Breast Cancer and Risk of Contralateral Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1752-1760.	3.0	25
78	Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 445-454.	1.1	25
79	Resource utilization after implementing a hospital-wide standardized feeding tube placement pathway. <i>Journal of Pediatric Surgery</i> , 2016, 51, 1674-1679.	0.8	25
80	Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER-Medicare Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1603-1610.	1.1	24
81	Alcohol, smoking, and risk of ER-overexpressing and triple-negative breast cancer relative to estrogen receptor-positive breast cancer. <i>International Journal of Cancer</i> , 2018, 143, 1849-1857.	2.3	23
82	The relationship between alcohol use and risk of breast cancer by histology and hormone receptor status among women 65-79 years of age. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 1061-6.	1.1	23
83	Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 481-489.	1.1	21
84	Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 611-618.	1.1	20
85	Breast Cancer With a Poor Prognosis Diagnosed After Screening Mammography With Negative Results. <i>JAMA Oncology</i> , 2018, 4, 998.	3.4	20
86	Relationship between Diabetes and Diabetes Medications and Risk of Different Molecular Subtypes of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1802-1808.	1.1	20
87	Genetic Variation in the Progesterone Receptor and Metabolism Pathways and Hormone Therapy in Relation to Breast Cancer Risk. <i>American Journal of Epidemiology</i> , 2009, 170, 1241-1249.	1.6	19
88	Relationship between diabetes and risk of second primary contralateral breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 545-551.	1.1	17
89	Alcohol Use and Breast Cancer Survival among Participants in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1268-1273.	1.1	17
90	Risk factors for cancer-related distress in colorectal cancer survivors: one year post surgery. <i>Journal of Cancer Survivorship</i> , 2020, 14, 305-315.	1.5	17

#	ARTICLE	IF	CITATIONS
91	Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 969-978.	0.5	15
92	Clinical Characteristics and Outcomes of Colorectal Cancer in the ColoCare Study: Differences by Age of Onset. <i>Cancers</i> , 2021, 13, 3817.	1.7	15
93	Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci. <i>Breast Cancer Research</i> , 2022, 24, 27.	2.2	15
94	Insulinlike Growth Factor Binding Protein-1 and Ghrelin Predict Health Outcomes Among Older Adults: Cardiovascular Health Study Cohort. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 267-278.	1.8	14
95	Postmenopausal hormone therapy and the risk of breast cancer: the view of an epidemiologist. <i>Maturitas</i> , 2004, 49, 44-50.	1.0	13
96	Breastfeeding and Triple-Negative Breast Cancer: Potential Implications for Racial/Ethnic Disparities. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	12
97	Family History and Risk of Second Primary Breast Cancer after <i>In Situ</i> Breast Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 315-320.	1.1	12
98	Relationship Between Anthropometric Factors and Risk of Second Breast Cancer Among Women With a History of Ductal Carcinoma In Situ. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky020.	1.4	12
99	<i>Fusobacterium nucleatum</i> and Clinicopathologic Features of Colorectal Cancer: Results From the ColoCare Study. <i>Clinical Colorectal Cancer</i> , 2021, 20, e165-e172.	1.0	12
100	Breast Cancer Biology and Clinical Characteristics. , 2010, , 21-46.		11
101	The Role of CT-Quantified Body Composition on Longitudinal Health-Related Quality of Life in Colorectal Cancer Patients: The Colocare Study. <i>Nutrients</i> , 2020, 12, 1247.	1.7	11
102	Circulating B-vitamin biomarkers and B-vitamin supplement use in relation to quality of life in patients with colorectal cancer: results from the FOCUS consortium. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1468-1481.	2.2	11
103	Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass. <i>Scientific Reports</i> , 2021, 11, 18156.	1.6	11
104	Bra Wearing Not Associated with Breast Cancer Risk: A Population-Based Caseâ€“Control Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2181-2185.	1.1	10
105	Rare loss of function variants in candidate genes and risk of colorectal cancer. <i>Human Genetics</i> , 2018, 137, 795-806.	1.8	10
106	Multiplatform Urinary Metabolomics Profiling to Discriminate Cachectic from Non-Cachectic Colorectal Cancer Patients: Pilot Results from the ColoCare Study. <i>Metabolites</i> , 2019, 9, 178.	1.3	10
107	Time to Follow-up After Colorectal Cancer Screening by Health Insurance Type. <i>American Journal of Preventive Medicine</i> , 2019, 56, e143-e152.	1.6	10
108	Multilevel Predictors of Continued Adherence to Breast Cancer Screening Among Women Ages 50â€“74 Years in a Screening Population. <i>Journal of Women's Health</i> , 2019, 28, 1051-1059.	1.5	10

#	ARTICLE	IF	CITATIONS
109	A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 564-575.	1.1	10
110	Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer. <i>Hormones and Cancer</i> , 2019, 10, 71-76.	4.9	9
111	Circulating Folate and Folic Acid Concentrations: Associations With Colorectal Cancer Recurrence and Survival. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa051.	1.4	9
112	Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence. <i>Current Opinion in Rheumatology</i> , 2021, 33, 292-299.	2.0	9
113	Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 439-447.	1.1	8
114	Use of Antihypertensive Medications Not Associated with Risk of Contralateral Breast Cancer among Women Diagnosed with Estrogen Receptor-Positive Invasive Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1423-1426.	1.1	8
115	Proteomic Analysis, Immune Dysregulation, and Pathway Interconnections with Obesity. <i>Journal of Proteome Research</i> , 2017, 16, 274-287.	1.8	8
116	Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3079-3093.	3.2	8
117	Postoperative Complications Are Associated with Long-Term Changes in the Gut Microbiota Following Colorectal Cancer Surgery. <i>Life</i> , 2021, 11, 246.	1.1	8
118	Discovery and Validation of Breast Cancer Early Detection Biomarkers in Preclinical Samples. <i>Hormones and Cancer</i> , 2011, 2, 125-131.	4.9	7
119	Alcohol Intake and Risk of Breast Cancer by Histologic Subtype and Estrogen Receptor Status Among Women Aged 55 to 74 Years. <i>Hormones and Cancer</i> , 2017, 8, 211-218.	4.9	7
120	Racial/ethnic disparities in risk of breast cancer mortality by molecular subtype and stage at diagnosis. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 549-558.	1.1	7
121	Trends in Distant-Stage Breast, Colorectal, and Prostate Cancer Incidence Rates from 1992 to 2004: Potential Influences of Screening and Hormonal Factors. <i>Hormones and Cancer</i> , 2010, 1, 55-62.	4.9	5
122	Obstetrical and infant outcomes among women with neoplasms during pregnancy. <i>Cancer Causes and Control</i> , 2019, 30, 651-661.	0.8	5
123	Reproductive and menopausal factors and risk of second primary breast cancer after in situ breast carcinoma. <i>Cancer Causes and Control</i> , 2019, 30, 113-120.	0.8	5
124	Response to Li and Hopper. <i>American Journal of Human Genetics</i> , 2021, 108, 527-529.	2.6	5
125	Presurgery Adhesion Molecules and Angiogenesis Biomarkers Are Differently Associated with Outcomes in Colon and Rectal Cancer: Results from the ColoCare Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1650-1660.	1.1	5
126	Recommendation to use exact P-values in biomarker discovery research in place of approximate P-values. <i>Cancer Epidemiology</i> , 2018, 56, 83-89.	0.8	4

#	ARTICLE	IF	CITATIONS
127	Hemochromatosis risk genotype is not associated with colorectal cancer or age at its diagnosis. <i>Human Genetics and Genomics Advances</i> , 2020, 1, 100010.	1.0	3
128	Antihypertensive medications and risks of recurrence and mortality in luminal, triple-negative, and HER2-overexpressing breast cancer. <i>Cancer Causes and Control</i> , 2021, 32, 1375-1384.	0.8	3
129	Changing incidence rate of invasive lobular breast carcinoma among older women. <i>Cancer</i> , 2000, 88, 2561-2569.	2.0	3
130	Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study. <i>Nutrients</i> , 2021, 13, 4164.	1.7	3
131	Bisphosphonate Use and Breast Cancer Risk among Women with Ductal Carcinoma <i>In Situ</i> . <i>Cancer Research</i> , 2021, 81, 2799-2802.	0.4	2
132	Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. , 2000, 88, 2570.		2
133	Determinants of Guideline-Discordant Breast Cancer Care. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 61-70.	1.1	2
134	Alcohol consumption, smoking, and invasive breast cancer risk after ductal carcinoma in situ. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 477-484.	1.1	2
135	Higher vitamin B6 status is associated with improved survival among patients with stage III colorectal cancer. <i>American Journal of Clinical Nutrition</i> , 2022, 116, 303-313.	2.2	2
136	Reply to reproductive and hormonal risk factors for postmenopausal luminal, HER2-overexpressing, and triple-negative breast cancer. <i>Cancer</i> , 2009, 115, 1803-1803.	2.0	1
137	Can Cost-effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1106-1113.	1.1	1
138	Exogenous Hormones. , 2010, , 89-117.		1
139	Association between antidepressant use and second breast cancer event after ductal carcinoma in situ diagnosis: a nested case-control study. <i>Cancer Causes and Control</i> , 2022, 33, 593.	0.8	1
140	Genetic Regulation of DNA Methylation Yields Novel Discoveries in GWAS of Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1068-1076.	1.1	1
141	Pathologic, Clinical, and Epidemiologic Characteristics of Invasive Lobular Breast Carcinoma and a Review of Studies Evaluating its Association with Hormone Replacement Therapy. , 2005, , 47-64.		0
142	Antihypertensive Medications and Breast Cancer Risk”Reply. <i>JAMA Internal Medicine</i> , 2014, 174, 641.	2.6	0
143	Endogenous Hormones. , 2010, , 73-87.		0
144	Associations between physical activity, sedentary behavior, and urinary oxidized guanine in colorectal cancer patients: results from the ColoCare Study. <i>Applied Physiology, Nutrition and Metabolism</i> , 2020, 45, 1306-1309.	0.9	0

#	ARTICLE	IF	CITATIONS
145	Disparities in risk of advanced stage liver cancer and mortality by race and ethnicity. Journal of the National Cancer Institute, 2022, , .	3.0	0